# US 12,290,554 B2 · Compositions for optimized BCR-ABL peptide vaccines > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,290,554 B2 - Document ID: US12290554B2 - Status: Granted - Kind: B2 - Application number: 17/934,067 - Filed: 2022-09-21 - Published: 2023-03-30 - Granted: 2025-05-06 - Earliest claimed: 2021-09-28 - Assignees: Think Therapeutics, Inc. - Applicants: Think Therapeutics, Inc. - Inventors: David Kenneth Gifford; Brandon Carter - Web page: https://patentgrep.com/patent/US12290554B2 ## CPC - A61K 39/001197: {Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]} - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - A61K 40/4201: {Neoantigens} - A61P 35/00: Antineoplastic agents - C12N 15/85: for animal cells - A61K 2039/51: {comprising whole cells, viruses or DNA/RNA} - A61K 2039/575: {humoral response} - C12N 2510/00: Genetically modified cells - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present disclosure provides for methods, systems, and compositions of nucleic acid and peptide sequences. The present disclosure provides for a nucleic acid sequence encoding two or more amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 44. The present disclosure also provides for an immunogenic peptide composition comprising two or more peptides selected from the group consisting of SEQ ID NOs: 1 to 44. The present disclosure further provides for a nucleic acid sequence encoding one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 46 to 112. The present disclosure additionally provides for an immunogenic peptide composition comprising one or more peptides selected from the group consisting of SEQ ID NOs: 46 to 112. ## Claims ### Claim 1 A composition comprising one or more polynucleotides encoding at least two amino acid sequences, wherein the at least two amino acid sequences are selected from the group consisting of SEQ ID NOs: 1 to 8, SEQ ID NOs: 10 to 17, and SEQ ID NOs: 19 to 44. ### Claim 2 (depends on 1) The composition of claim 1, wherein the one or more polynucleotides are contained in a construct for in vivo expression of the one or more polynucleotides. ### Claim 3 (depends on 2) The composition of claim 2, wherein an administration of the one or more polynucleotides causes one or more peptides encoded by the or more polynucleotides to be displayed by an HLA class I molecule present in a subject. ### Claim 4 (depends on 3) The composition of claim 3, wherein the one or more polynucleotides are contained in a construct for in vivo expression of at least two peptides encoded by the one or more polynucleotides, wherein an administration of the one or more polynucleotides to the subject causes: a first peptide of the at least two peptides to be displayed by a first plurality of HLA class I alleles present in the subject; and a second peptide of the at least two peptides to be displayed by a second plurality of HLA class I alleles present in the subject, wherein the first plurality of HLA class I alleles and the second plurality of HLA class I alleles differ by at least one HLA class I allele. ### Claim 5 (depends on 3) The composition of claim 3, wherein the one or more peptides is a modified or an unmodified fragment of a BCL-ABL gene fusion. ### Claim 6 (depends on 5) The composition of claim 5, wherein the BCR-ABL gene fusion is b3a2 or b2a2. ### Claim 7 (depends on 5) The composition of claim 5, wherein the two or more amino acid sequences are selected based on a prevalence of the BCR-ABL gene fusion in a risk group that the subject belongs to, and wherein the composition is configured for administration in an effective amount to the subject to promote an immune response against cancer, and wherein the cancer is associated with the BCR-ABL gene fusion. ### Claim 8 (depends on 3) The composition of claim 3, wherein the one or more polynucleotides are configured for administration in an effective amount to the subject to treat cancer. ### Claim 9 A composition comprising one or more polynucleotides encoding one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 46 to 112. ### Claim 10 (depends on 9) The composition of claim 9, wherein the one or more polynucleotides are contained in a construct for in vivo expression of the one or more polynucleotides. ### Claim 11 (depends on 10) The composition of claim 10, wherein an administration of the one or more polynucleotides causes one or more peptides encoded by the one or more polynucleotides to be displayed by an HLA class II molecule present in a subject. ### Claim 12 (depends on 11) The composition of claim 11, wherein the one or more amino acid sequences are derived from a modified or an unmodified fragment of a BCL-ABL gene fusion. ### Claim 13 (depends on 12) The composition of claim 12, wherein the BCR-ABL gene fusion is b3a2 or b2a2. ### Claim 14 (depends on 12) The composition of claim 12, wherein the one or more amino acid sequences are selected based on a prevalence of the BCR-ABL gene fusion in a risk group that the subject belongs to, and wherein the composition is configured for administration in an effective amount to the subject to promote an immune response against cancer, and wherein the cancer is associated with the BCR-ABL gene fusion. ### Claim 15 (depends on 11) The composition of claim 11, wherein the composition is configured for administration in an effective amount to the subject to treat cancer, wherein the cancer is associated with the BCR-ABL gene fusion. ### Claim 16 (depends on 9) The composition of claim 9, wherein the one or more polynucleotides encode at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 46 to 112.